Discover Atai Life Sciences N.V.'s 275% YTD surge, driven by innovative psychedelic therapies for TRD. Click for my ATAI stock update and why I remain bullish.

In 1967, two psychiatrists set out to quantify the weight of our experiences and how significant their impacts are to our well-being, creating the Social Readjustment Rating Scale (SRRS). Beyond the ...

A new study suggests that a well-formulated ketogenic diet, followed for at least 10 weeks, is associated with a significant reduction in depression symptoms among a small group of college students.

A phase 2 trial suggests that the novel SNRI ammoxetine may effectively treat major depressive disorder while avoiding some side effects common to other antidepressants.

Personalized high-definition transcranial direct current stimulation is linked to improved outcomes in moderate-to-severe depression compared to sham therapy, a new trial shows.

An investigational drug did not significantly improve outcomes versus quetiapine extended release (Seroquel XR) as an adjunctive treatment in adults with major depressive disorder (MDD) and insomnia ...

SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative therapies, today announced that results from its ...

From St John’s Wort to vitamin D: This review uncovers which over-the-counter products have real scientific backing for relieving depression, and which still need proof. Study: Understanding the ...